243 related articles for article (PubMed ID: 36059642)
1. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
Front Oncol; 2022; 12():957068. PubMed ID: 36059642
[TBL] [Abstract][Full Text] [Related]
2. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
Abdel-Rahman O
Tumour Biol; 2014 Nov; 35(11):10615-25. PubMed ID: 25230786
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
[No Abstract] [Full Text] [Related]
7. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
Xu J
Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Weber MM; Fottner C
Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
[TBL] [Abstract][Full Text] [Related]
9. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Pelle' E; Strosberg J
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
12. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
13. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
Takayanagi D; Cho H; Machida E; Kawamura A; Takashima A; Wada S; Tsunoda T; Kohno T; Shiraishi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267427
[TBL] [Abstract][Full Text] [Related]
14. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
16. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
[TBL] [Abstract][Full Text] [Related]
17. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
18. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.
Corti F; Rossi RE; Cafaro P; Passarella G; Turla A; Pusceddu S; Coppa J; Oldani S; Guidi A; Longarini R; Cortinovis DL
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893145
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
